compounded tirzepatide b6 + (Pyridoxine) | 10mL Multi-Dose Weight Loss Injection Compounded Tirzepatide (GLP-1/GIP)

Aim for at least 8 glasses of water a day (more if tolerated)

DPP-4 inhibitors may be preferred for: Patients unable or unwilling to use injectable therapies Elderly individuals where the lower hypoglycaemia risk is particularly valuable Those at high risk of hypoglycaemia from other medications Patients requiring modest glycaemic improvements Individuals where weight neutrality is acceptable or desired Important cautions and contraindications: Do not combine a GLP-1 receptor agonist with a DPP-4 inhibitor

For comparisons among three or more groups, one-way ANOVA followed by Tukeys post hoc test was applied

How epithalon is thought to work The proposed mechanisms of epithalon are still being investigated and should be described with appropriate hedging

Industry standard is to report all SAEs within 24 hours to the sponsor who then must report to FDA within 7 days (death, life-threatening) or 15 days (other SAE)

Research into GLP-1 use in IBD is limited but growing